The IABP-SHOCK II study

(Press-News.org) Munich, Germany – A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people. However, there is still only limited evidence that the intraaortic balloon pump (IABP), one of the oldest medical devices in cardiology, is actually beneficial for the patient. Only a few registry studies and clinical trials have shown that the IABP can improve blood pressure and the perfusion of the coronary arteries.

Based on these studies, international guidelines recommend the use of an IABP in patients with cardiogenic shock. However, because cardiologists are not entirely convinced of its efficacy, an IABP is currently used in only 25-40% of shock patients. It was for these reasons that the IABP-SHOCK II trial was designed, aiming to show that the IABP can improve mortality if used in conjunction with optimal medical therapy and early reopening of the infarct-related artery.

Approximately 5-10% of patients after a heart attack experience the complication of cardiogenic shock, a shock which results from an inability of the heart to meet the body's demand for oxygen. In Europe around 60-70,000 patients are diagnosed with cardiogenic shock each year. In the past decade mortality related to cardiogenic shock has been reduced, mainly by early reopening of the infarct-affected artery by early balloon inflation. Nevertheless, the mortality rate in these patients is still extremely high, with approximately 50% dying within the first 30 days.

The IABP-SHOCK II trial - the largest trial ever performed in cardiogenic shock - randomised 600 patients enrolled in 37 centres in Germany to either an IABP or conventional optimal medical treatment alone. The hypothesis tested was that the IABP could reduce the rate of mortality within 30 days.

However, the study found no reduction in 30-day mortality rate in the IABP group when compared to the control group having standard care alone. The primary results are shown in the Figure attached, with no effect over time between the two study groups. Several subgroups were also evaluated and here too there was no clear benefit found for the IABP.

Similarly, the IABP showed no improvement in blood pressure, no reduction in treatment time in the intensive care unit, no decrease in the duration or dose of drugs prescribed, and no improvement in organ perfusion. On the other hand, the trial results showed that the IABP did not induce complications, and was shown to be a safe device.

Presenting the results, Professor Holger Thiele from the University of Leipzig Heart Centre in Germany said: "This large multicentre trial was unable to show a benefit for the currently most widely used mechanical support device in cardiogenic shock."

### Because of its importance, the trial was supported by the German Research Foundation, the German Heart Research Foundation, the German Cardiac Society, the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte, and also partly funded by unrestricted grants from Maquet Cardiopulmonary AG, Hirrlingen, Germany and Teleflex Medical, Everett, MA, USA.

Notes to editors

Please note that the author's photo and CV as well as the spokesperson's CV can be found here

About the European Society of Cardiology www.escardio.org The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2012 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available at: http://spo.escardio.org/Welcome.aspx?eevtid=54 More information is available from the ESC Press Office at press@escardio.org. END